Genomic Profiling of Advanced Non–Small Cell Lung Cancer in Community Settings: Gaps and Opportunities

Clinical Lung Cancer

Volumn 18, Issue 6, 2017, Pages 651-659

  Gutierrez, Martin E ^a   Choi, Kelly ^b   Lanman, Richard B ^c   Licitra, Edward J ^d   Skrzypczak, Stanley M ^c   Pe Benito, Ruth ^b   Wu, Tommy ^b   Arunajadai, Srikesh ^b   Kaur, Sukhi ^b   Harper, Harry ^a   Pecora, Andrew L ^d   Schultz, Eric V ^b   Goldberg, Stuart L ^b  

^a HACKENSACK UNIVERSITY MEDICAL CENTER   (United States)

^b COTA Inc ^*  (United States)

^c Guardant Health   (United States)

^d Regional Cancer Care Associates   (United States)

Author keywords

Matched therapy; Next generation sequencing; NSCLC; Targeted therapy; Under genotyping

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; B RAF KINASE; BEVACIZUMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; PEMETREXED; PROTEIN RET; ANTINEOPLASTIC AGENT; EGFR PROTEIN, HUMAN; PROTEIN TYROSINE KINASE; TUMOR MARKER;

ADULT; ADVANCED CANCER; AGE; AGED; ARTICLE; CANCER GENETICS; CANCER SURVIVAL; COPY NUMBER VARIATION; FEMALE; GENE AMPLIFICATION; GENE EXPRESSION PROFILING; GENE FREQUENCY; GENE FUSION; GENOMICS; HUMAN; HUMAN TISSUE; INDEL MUTATION; MAJOR CLINICAL STUDY; MALE; NEXT GENERATION SEQUENCING; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; PATIENT REFERRAL; POINT MUTATION; PRACTICE GUIDELINE; RACE DIFFERENCE; RETROSPECTIVE STUDY; SEX DIFFERENCE; TERTIARY CARE CENTER; CANCER STAGING; CLINICAL PRACTICE; COMMUNITY CARE; GENETIC SCREENING; GENETICS; GENOTYPE; LUNG TUMOR; MARYLAND; METABOLISM; MIDDLE AGED; MUTATION; NEW JERSEY; ONCOLOGIST; PATHOLOGY; PROCEDURES; PROTOCOL COMPLIANCE; STATISTICS AND NUMERICAL DATA;

AGED; ANTINEOPLASTIC AGENTS; BIOMARKERS, TUMOR; CARCINOMA, NON-SMALL-CELL LUNG; COMMUNITY HEALTH SERVICES; FEMALE; GENETIC TESTING; GENOMICS; GENOTYPE; GUIDELINE ADHERENCE; HUMANS; LUNG NEOPLASMS; MALE; MARYLAND; MIDDLE AGED; MUTATION; NEOPLASM STAGING; NEW JERSEY; ONCOLOGISTS; PRACTICE GUIDELINES AS TOPIC; PRACTICE PATTERNS, PHYSICIANS'; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RETROSPECTIVE STUDIES;

EID: 85019001567     PISSN: 15257304     EISSN: 19380690     Source Type: Journal    
DOI: 10.1016/j.cllc.2017.04.004     Document Type: Article

References (53)

1. Siegel, R.L., Miller, K.D., Jemal, A., Cancer statistics, 2007. CA Cancer J Clin 67 (2017), 7–30.
2. Jemal, A., Bray, F., Center, M.M., Ferlay, J., Ward, E., Forman, D., Global cancer statistics. CA Cancer J Clin 61 (2011), 69–90.
3. Scheff, R.J., Schneider, B.J., Non-small-cell lung cancer: treatment of late stage disease: chemotherapeutics and new frontiers. Semin Interv Radiol 30 (2013), 191–198.
4. Cardarella, S., Johnson, B.E., The impact of genomic changes on treatment of lung cancer. Am J Respir Crit Care Med 188 (2013), 770–775.
5. Garon, E.B., Rizvi, N.A., Hui, R., et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med 372 (2015), 2018–2028.
6. Borghaei, H., Paz-Ares, L., Horn, L., et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 373 (2015), 1627–1639.
7. Mok, T.S., Wu, Y.-L., Thongprasert, S., et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361 (2009), 947–957.
8. Zhou, C., Wu, Y.-L., Chen, G., et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 12 (2011), 735–742.
9. Sequist, L.V., Yang, J.C.-H., Yamamoto, N., et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol 31 (2013), 3327–3334.
10. Zhao, H., Fan, Y., Ma, S., et al. Final overall survival results from a phase III, randomized, placebo-controlled, parallel-group study of gefitinib versus placebo as maintenance therapy in patients with locally advanced or metastatic non-small-cell lung cancer (INFORM; C-TONG 0804). J Thorac Oncol 10 (2015), 655–664.
11. Shaw, A.T., Kim, D.-W., Nakagawa, K., et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 368 (2013), 2385–2394.
12. Shaw, A.T., Ou, S.-H.I., Bang, Y.-J., et al. Crizotinib in ROS1-rearranged non–small-cell lung cancer. N Engl J Med 371 (2014), 1963–1971.
13. Nokihara, H., Hida, T., Kondo, M., et al. Alectinib (ALC) versus crizotinib (CRZ) in ALK-inhibitor naive ALK-positive non-small cell lung cancer (ALK+ NSCLC): primary results from the J-ALEX study. J Clin Oncol, 34(suppl), 2016 abstract 9008.
14. Planchard, D., Besse, B., Groen, H.J.M., et al. Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial. Lancet Oncol 17 (2016), 984–993.
15. Paik, P.K., Drilon, A., Fan, P.-D., et al. Response to MET inhibitors in patients with stage IV lung adenocarcinomas harboring MET mutations causing exon 14 skipping. Cancer Discov 5 (2015), 842–849.
16. Drilon, A., Wang, L., Hasanovic, A., et al. Response to cabozantinib in patients with RET fusion-positive lung adenocarcinomas. Cancer Discov 3 (2013), 630–635.
17. Mazières, J., Barlesi, F., Filleron, T., et al. Lung cancer patients with HER2 mutations treated with chemotherapy and HER2-targeted drugs: results from the European EUHER2 cohort. Ann Oncol 27 (2016), 281–286.
18. Cancer Genome Atlas Research Network. Comprehensive molecular profiling of lung adenocarcinoma. Nature 511 (2014), 543–550.
19. Lindeman, N.I., Cagle, P.T., Beasley, M.B., et al. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. J Thorac Oncol 8 (2013), 823–859.
20. Leighl, N.B., Rekhtman, N., Biermann, W.A., et al. Molecular testing for selection of patients with lung cancer for epidermal growth factor receptor and anaplastic lymphoma kinase tyrosine kinase inhibitors: American Society of Clinical Oncology endorsement of the College of American Pathologists/International Association for the Study of Lung Cancer/Association for Molecular Pathology guideline. J Clin Oncol 32 (2014), 3673–3679.
21. Ettinger, D.S., Wood, D.E., Akerley, W., et al. Non-small cell lung cancer, version 6.2015. J Natl Compr Cancer Netw 13 (2015), 515–524.
22. Cagle, P.T., Raparia, K., Portier, B.P., Emerging biomarkers in personalized therapy of lung cancer. Adv Exp Med Biol 890 (2016), 25–36.
23. Novello, S., Barlesi, F., Califano, R., et al. Metastatic non-small-cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 27:suppl 5 (2016), v1–v27.
24. Frampton, G.M., Ali, S.M., Rosenzweig, M., et al. Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors. Cancer Discov 5 (2015), 850–859.
25. Meric-Bernstam, F., Brusco, L., Shaw, K., et al. Feasibility of large-scale genomic testing to facilitate enrollment onto genomically matched clinical trials. J Clin Oncol 33 (2015), 2753–2762.
26. Centers for Medicare and Medicaid Services, Health and Human Services. §414.510 Laboratory Date of Service for Clinical Laboratory and Pathology Specimens. 2016. Available at: https://www.cms.gov/Regulations-and-Guidance/Guidance/Manuals/downloads/clm104C16.pdf. Accessed: March 21, 2017.
27. Schwaederle, M., Parker, B.A., Schwab, R.B., et al. Molecular tumor board: the University of California-San Diego Moores Cancer Center experience. Oncologist 19 (2014), 631–636.
28. Lim, C., Tsao, M.S., Le, L.W., et al. Biomarker testing and time to treatment decision in patients with advanced nonsmall-cell lung cancer. Ann Oncol 26 (2015), 1415–1421.
29. R Project for Statistical Computing. R: A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation: 2016. Available at: https://www.R-project.org/. Accessed: March 21, 2017.
30. Awad, M.M., Oxnard, G.R., Jackman, D.M., et al. MET exon 14 mutations in non-small-cell lung cancer are associated with advanced age and stage-dependent MET genomic amplification and c-Met overexpression. J Clin Oncol 34 (2016), 721–730.
31. Inal, C., Yilmaz, E., Cheng, H., et al. Effect of reflex testing by pathologists on molecular testing rates in lung cancer patients: experience from a community based academic center. J Clin Oncol, 32(15 suppl), 2014 (abstract 8098).
32. Spicer, J., Tischer, B., Peters, M., EGFR mutation testing and oncologist treatment choice in advanced NSCLC: global trends and differences. Ann Oncol 26 (2015), i57–i61.
33. Schink, J.C., Trosman, J.R., Weldon, C.B., et al. Biomarker testing for breast, lung, and gastroesophageal cancers at NCI designated cancer centers. J Natl Cancer Inst, 106, 2014.
34. Kris, M.G., Johnson, B.E., Berry, L.D., et al. Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. JAMA 311 (2014), 1998–2006.
35. Lokhandwala, T., Bittoni, M.A., Dann, R.A., et al. Costs of diagnostic assessment for lung cancer: a Medicare claims analysis. Clin Lung Cancer 18 (2016), 327–334.
36. Hagemann, I.S., Devarakonda, S., Lockwood, C.M., et al. Clinical next-generation sequencing in patients with non-small cell lung cancer. Cancer 121 (2015), 631–639.
37. Villaflor, V., Won, B., Nagy, R., et al. Biopsy-free circulating tumor DNA assay identifies actionable mutations in lung cancer. Oncotarget 7 (2016), 66880–66891.
38. Thompson, J.C., Yee, S.S., Troxel, A.B., et al. Detection of therapeutically targetable driver and resistance mutations in lung cancer patients by next-generation sequencing of cell-free circulating tumor DNA. Clin Cancer Res 22 (2016), 5772–5782.
39. Cunanan, K.M., Gonen, M., Shen, R., et al. Basket trials in oncology: a trade-off between complexity and efficiency. J Clin Oncol 35 (2017), 271–273.
40. Herbst, R.S., Gandara, D.R., Hirsch, F.R., et al. Lung master protocol (Lung-MAP)—a biomarker-driven protocol for accelerating development of therapies for squamous cell lung cancer: SWOG S1400. Clin Cancer Res 21 (2015), 1514–1524.
41. Colwell, J., NCI-MATCH trial draws strong interest. Cancer Discov, 6, 2016, 334.
42. Rozenblum, A.B., Ilouze, M., Dudnik, E., et al. Clinical impact of hybrid capture-based next-generation sequencing on changes in treatment decisions in lung cancer. J Thorac Oncol 12 (2017), 258–268.
43. Lebofsky, R., Decraene, C., Bernard, V., et al. Circulating tumor DNA as a non-invasive substitute to metastasis biopsy for tumor genotyping and personalized medicine in a prospective trial across all tumor types. Mol Oncol 9 (2015), 783–790.
44. Piotrowska, Z., Sequist, L.V., Treatment of EGFR-mutant lung cancers after progression in patients receiving first-line EGFR tyrosine kinase inhibitors: a review. JAMA Oncol 2 (2016), 948–954.
45. Russo, M., Siravegna, G., Blaszkowsky, L.S., et al. Tumor heterogeneity and lesion-specific response to targeted therapy in colorectal cancer. Cancer Discov 6 (2016), 147–153.
46. Goyal, L., Saha, S.K., Liu, L.Y., et al. Polyclonal secondary FGFR2 mutations drive acquired resistance to FGFR inhibition in patients with FGFR2 fusion-positive cholangiocarcinoma. Cancer Discov 7 (2016), 252–263.
47. Lanman, R.B., Mortimer, S.A., Zill, O.A., et al. Analytical and clinical validation of a digital sequencing panel for quantitative, highly accurate evaluation of cell-free circulating tumor DNA. PLoS One, 10, 2015, e0140712.
48. Lee, J., Kim, S.T., Kim, K.-M., Kang, W.K., Talasaz, A., Park, K., Cell-free DNA sequencing-guided therapy in a prospective clinical trial: NEXT-2 trial—a feasibility analysis. J Clin Oncol, 34(15 suppl), 2016 abstract 11534.
49. Henk, H.J., Ray, S., Treatment patterns and healthcare costs among patients with advanced non-small-cell lung cancer. Lung Cancer Manag 2 (2013), 189–197.
50. Oxnard, G.R., Thress, K.S., Alden, R.S., et al. Association between plasma genotyping and outcomes of treatment with osimertinib (AZD9291) in advanced non-small-cell lung cancer. J Clin Oncol 34 (2016), 3375–3382.
51. Mok, T.S., Wu, Y.-L., Ahn, M.-J., et al. Osimertinib or platinum–pemetrexed in EGFR T790M-positive lung cancer. N Engl J Med 376 (2017), 629–640.
52. Mok, T., Wu, Y.-L., Lee, J.S., et al. Detection and dynamic changes of EGFR mutations from circulating tumor DNA as a predictor of survival outcomes in NSCLC patients treated with first-line intercalated erlotinib and chemotherapy. Clin Cancer Res 21 (2015), 3196–3203.
53. Levy, B.P., Chioda, M.D., Herndon, D., et al. Molecular testing for treatment of metastatic non-small cell lung cancer: how to implement evidence-based recommendations. Oncologist 20 (2015), 1175–1181.